ARE SSRI’S EQUALLY SAFE IN PREGNANCY?
FLUOXETINE AND CITALOPRAM
EXPERIMENTAL STUDY
BIANCA EUGENIA ÖSZ1, CAMIL EUGEN VARI1*, MELINDA
KOLCSÀR1, OVIDIU SIMION COTOI2, MARIUS ȘTEFAN
MĂRUȘTERI3, MARIA T. DOGARU1
1Department of Pharmacology and Clinical Pharmacy, Faculty of
Pharmacy, University of Medicine and Pharmacy, Târgu Mureș
2Department of Cellular and Molecular Biochemistry, Faculty of
Medicine, University of Medicine and Pharmacy, Târgu Mureș
3Department of Medical Informatics and Biostatistics, Faculty of
Medicine, University of Medicine and Pharmacy, Târgu Mureș
* corresponding author: camil.vari@umftgm.ro
Download Full Article

Abstract:

The aim of the present study was to determine how fluoxetine and citalopram are
affecting gestation and fetal development in Wistar rats. Forty sexually mature female rats,
divided in two experimental groups received 20 mg/kg body weight fluoxetine or 3 mg/kg
body weight citalopram during the entire gestation period starting day one. Drugs were
administered by oral route. A control group (20 females) received distilled water by oral
gavage in the same conditions. Healthy males were caged with nulliparous females for an
entire week. All females were killed with halothane through gas scavenging apparatus
untilled death on assumed day 21 of gestation for examination of their uterine contents. The
number of healthy foetuses, resorbtions and dead foetuses were noted. In both experimental
groups resorbtion occurred and dead foetuses were identified. The resorbtions were
confirmed by histopathological analyses. The statistical analysis of results showed that only
citalopram is affecting gestation in a significant manner (p<0.01). For fluoxetine the
number of resorbtions and death foetuses was not significant different compared with
control group (p>0.05).

Top